Atezolizumab,Carboplatin,Etoposide,Tiragolumab
Roche
['lcsm,(-blcsm)', 'sclc']
skyscraper-2: tigit added to 1l chemoio in sclc disappointing but perhaps not unexpected. as ever, sclc proving resistant to advances in treatment. one plus is absence of significant toxicity, except low grade pruritis #lcsm #asco22 
Thoracic medical oncologist | Consultant @ChelwestFT | Vice Chair @BTOGorg | Skier, when snow permits.